Patient characteristics
| Patient characteristics (N = 50) . | n (%) or [range] . |
|---|---|
| Age, median | 72 [56-85] |
| Male | 28 (56) |
| Median baseline laboratory values | |
| Hemoglobin (Hb) (g/dL) | 8.7 [4.4-12] |
| WBC (×103/μL) | 5.9 [1.1-38] |
| Platelets (×103/μL) | 52 [6-1365] |
| Spleen size by palpitation (n = 30), cm | 12 [1-30] |
| Prior treatment history | |
| ≥2 Prior treatments | 37 (74) |
| Prior JAK inhibitor | 28 (56) |
| Prior immunomodulatory agents | 12 (24) |
| Prior SCT | 2 (4) |
| IPSS (baseline) | |
| Intermediate-1 risk | 2 (4) |
| Intermediate-2 risk | 11 (22) |
| High risk | 37 (74) |
| Patient characteristics (N = 50) . | n (%) or [range] . |
|---|---|
| Age, median | 72 [56-85] |
| Male | 28 (56) |
| Median baseline laboratory values | |
| Hemoglobin (Hb) (g/dL) | 8.7 [4.4-12] |
| WBC (×103/μL) | 5.9 [1.1-38] |
| Platelets (×103/μL) | 52 [6-1365] |
| Spleen size by palpitation (n = 30), cm | 12 [1-30] |
| Prior treatment history | |
| ≥2 Prior treatments | 37 (74) |
| Prior JAK inhibitor | 28 (56) |
| Prior immunomodulatory agents | 12 (24) |
| Prior SCT | 2 (4) |
| IPSS (baseline) | |
| Intermediate-1 risk | 2 (4) |
| Intermediate-2 risk | 11 (22) |
| High risk | 37 (74) |